187 related articles for article (PubMed ID: 37304259)
1.
Malli C; Pandit L; D'Cunha A; Sudhir A
Front Immunol; 2023; 14():1162248. PubMed ID: 37304259
[TBL] [Abstract][Full Text] [Related]
2. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
3. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
[TBL] [Abstract][Full Text] [Related]
5. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
[TBL] [Abstract][Full Text] [Related]
6. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V;
Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777
[TBL] [Abstract][Full Text] [Related]
7. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Wang M; Xia D; Sun L; Bi J; Xie K; Wang P
Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033
[TBL] [Abstract][Full Text] [Related]
10. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
Lin L; Wu Y; Hang H; Lu J; Ding Y
Front Immunol; 2022; 13():853891. PubMed ID: 35898513
[TBL] [Abstract][Full Text] [Related]
11. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
[TBL] [Abstract][Full Text] [Related]
12. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
[TBL] [Abstract][Full Text] [Related]
13. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.
Wang L; Xia R; Li X; Shan J; Wang S
Front Immunol; 2023; 14():1293100. PubMed ID: 38259484
[TBL] [Abstract][Full Text] [Related]
14. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
[TBL] [Abstract][Full Text] [Related]
15. Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
Gernert JA; Wicklein R; Hemmer B; Kümpfel T; Knier B; Havla J
J Neurol; 2023 Feb; 270(2):1135-1140. PubMed ID: 36245037
[TBL] [Abstract][Full Text] [Related]
16. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
17. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
[TBL] [Abstract][Full Text] [Related]
18. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
19. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C
J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103
[TBL] [Abstract][Full Text] [Related]
20. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
